



CIN : L99999MH1951PLC008485

Regd. Office : A-1601, Thane One, DIL Complex, Ghodbunder Road, Majiwada, Thane (West) 400 610, Maharashtra, India

Tel : +91-22-67980888 , ● Fax : +91-22-67980899 , ● Email : [contact@dil.net](mailto:contact@dil.net) , ● Website : [www.dil.net](http://www.dil.net)

Ref: DIL:DIL/BSE/2018-19/F.No.:S-23/ DE05

May 15, 2018

**Corporate Relations  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai – 400 001**

Dear Sir,

**Sub.: Intimation of Investors Release dated May 15, 2018**

**Ref: Scrip Code: 506414**

Further to our intimation dated May 15, 2018 regarding approval of Audited Financial Results (Standalone and Consolidated) by the Board of Directors for the quarter and year ended March 31, 2018, we hereby enclose a copy of Investors Release of the Company dated May 15, 2018 for the financial year ended March 31, 2018.

The said Investors Release is also available on Company's website [www.dil.net](http://www.dil.net)

Kindly take the same on records.

Thanking you,

Yours faithfully,  
for **DIL LIMITED**

**Srikant N Sharma**  
**Company Secretary**  
CS Membership No: F3617  
*A-1601, Thane One, DIL Complex, Ghodbunder Road, Majiwade, Thane (W) 400610*

Encl: As above

## DIL Limited

### FY18 Consolidated Performance:

- Total Revenue at Rs. 311.92 Cr. growth of 85% YoY
- EBITDA Rs. 101.96 Cr. (32.68% of Revenues), YoY growth of ~592%
- PAT before share of profit/(loss) of associates and joint-venture and non-controlling interests Rs. 54.83 Cr as against Negative Rs. 8.23 Cr the previous year
- Board of Directors proposed final equity dividend of Rs. 2.50 per share (Face Value Rs. 10), based on DIL's standalone annual financial statement

**Mumbai, 15<sup>th</sup> May 2018:** Consolidated financial results of DIL Limited for the year ended March 31, 2018.

DIL Limited (Consolidated Results)						
Particulars (Rs. Crs)	Q4 FY18	Q4 FY17	YoY%	FY18	FY17	YoY%
Revenue	101.40	44.89	126%	311.92	168.47	85%
EBITDA	42.64	5.47	680%	101.96	14.74	592%
Margin (%)	42.05%	12.18%		32.68%	8.75%	
PAT before share of profit/(loss) of associates and joint-venture and non-controlling interests	25.70	(0.38)		54.83	(8.23)	
Margin (%)	25.35%	(0.85%)		17.58%	(4.89%)	

### Fermenta Biotech Limited, 91.2% Subsidiary of DIL Limited

Fermenta Biotech Limited (FBL) manufactures Vitamin D3 (Cholecalciferol), the only manufacturer and supplier in India and amongst the top few global manufacturers. Apart from Vitamin D3, it also manufactures niche APIs', and is a major supplier of Penicillin G Amidase, Polymer Supports and enzyme technologies for beta lactams and Bio-Enzymes for Environmental Solutions.

## Investors Release

Fermenta Biotech Limited						
Particulars (Rs. Crs)	Q4 FY18	Q4 FY17	YoY%	FY18	FY17	YoY%
Revenue	97.56	43.12	126%	300.48	163.12	84%
EBITDA	39.76	7.57	425%	103.18	22.97	349%
Margin (%)	40.75%	17.56%		34.34%	14.08%	
PAT	28.94	4.45	550%	72.06	10.34	597%
Margin (%)	29.24%	10.33%		23.98%	6.33%	

- Revenues of Rs. 300.48 Cr for FY18 as against Rs. 163.12 Cr in FY17, up by 84% YoY. Growth in revenues attributable to increased volumes of Vitamin D3 and higher price realization from sales of Vitamin D3 Feed Grade Powder
- EBITDA Rs. 103.18 Cr (34.34% of revenues) for FY18 as against Rs. 22.97 Cr. (14.08% of revenues) in FY17
- PAT of Rs. 72.06 Cr in FY 18 as against Rs. 10.34 Cr in FY 17; growth of 596.9% YoY

### **Commenting on the performance Mr. Satish Varma, Managing Director, Fermenta Biotech Limited said**

“As a leading player in the Vitamins industry, we are pleased with our increased market share in the global Vitamin D3 market. Our investment over the last few years in our manufacturing capacities and focus on quality has helped the Company continuously expand its footprint globally and meet the increasing demand for Vitamin D3.

With the many essential benefits of Vitamin D3 and its role in most of the body's vital processes becoming more and more recognized and accepted, we are confident of our continued growth in the coming years in both the domestic as well as international markets. Our continued focus on manufacturing quality products complemented with in-house R&D, will help us maintain our established position in this growing market.”

## Investors Release

### **About DIL Limited:**

DIL holds 91.2% equity stake in Fermenta Biotech Limited (FBL), which was incorporated in 1986.

FBL is engaged in manufacturing of Vitamin D3, other specialty API's, biological enzymes and also offers integrated biotech based environmental solutions. FBL has 2 manufacturing facilities:

- Kullu in Himachal Pradesh – cGMP certified and currently manufactures vitamin D3, specialty API's and Enzymes
- Dahej SEZ – set up in 2011 and manufactures Vitamin D3

DIL has developed premium office spaces named 'THANE ONE', with a total leasable area of 200,000 sq. ft., which is currently about 95% occupied.

For more information about the Company and its businesses, please visit our website [www.dil.net](http://www.dil.net)

### **Safe Harbor:**

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

### **For further details please contact:**

Company	Investor Relations Advisors
<p><b>DIL Limited</b>            CIN No: L99999MH1951PLC008485            Name: Sumesh Gandhi            Email id: <a href="mailto:sumesh.gandhi@dil.net">sumesh.gandhi@dil.net</a></p>	<p><b>Strategic Growth Advisors Pvt Ltd.</b>            CIN No: U74140MH2010PTC204285            Rahul Agarwal / Nirali Shah            Email id: <a href="mailto:rahul.agarwal@sgapl.net">rahul.agarwal@sgapl.net</a>  <a href="mailto:Nirali.shah@sgapl.net">Nirali.shah@sgapl.net</a>            Tel No: +91 79770 90416 / +91 97736 17347</p>